Drugs / Aroplatin
Aroplatin
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00316511 | Mar 2006 → Jun 2008 | B-cell neoplasm, cancer | Agenus Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT00081549 | — | pancreatic neoplasm | Aronex Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT00057395 | — | colorectal neoplasm, hepatocellular carcinoma, neoplasm of esophagus, ovarian neoplasm +1 | Aronex Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT00081536 | — | colorectal neoplasm | Aronex Pharmaceuticals | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00043199 | — | colorectal neoplasm | Aronex Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aroplatin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00043199 ↗ |
| Known as | L-NDDP | “Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma” NCT00316511 ↗3“Aroplatin (Liposomal NDDP, L-NDDP)” NCT00043199 ↗ “Aroplatin (Liposomal NDDP, L-NDDP)” NCT00057395 ↗ “Aroplatin (Liposomal NDDP, L-NDDP)” NCT00081549 ↗ |
| Known as | Liposomal NDDP | “Aroplatin (Liposomal NDDP) in combination with capecitabine” NCT00081536 ↗3“Aroplatin (Liposomal NDDP, L-NDDP)” NCT00043199 ↗ “Aroplatin (Liposomal NDDP, L-NDDP)” NCT00081549 ↗ “Aroplatin (Liposomal NDDP, L-NDDP)” NCT00057395 ↗ |
| Modality | Small molecule | — CHEMBL4297263 ↗ |